However, further investigation is necessary to avoid or minimize undesirable side effects such as cytokine release syndrome (CRS) as well as the development of CAR cells secreting engager molecules against HER2-altered CCA. This evidence concerns the gene ERBB2 and cholangiocarcinoma.